Remission Rate in the Patients with Graves' Disease after Treatment with a Minimum Maintenance Dose of Methimazole for 12 Months

被引：0
|
作者：
Mutsuo, Beniko [1 ]
Hiroyuki, Ikawa [1 ]
Takayuki, Mori [1 ]
Yasuo, Mashio [2 ]
机构：
[1] Sapporo Kosei Gen Hosp, Sapporo, Hokkaido, Japan
[2] Sapporo Kosei Kyosai Clin, Sapporo, Hokkaido, Japan
来源：
ENDOCRINE REVIEWS | 2014年 / 35卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
MON-0471
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
    Tanaka, Yoshiya
    Smolen, Josef S.
    Jones, Heather
    Szumski, Annette
    Marshall, Lisa
    Emery, Paul
    ARTHRITIS RESEARCH & THERAPY, 2019, 21 (1)
  • [42] The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
    Yoshiya Tanaka
    Josef S. Smolen
    Heather Jones
    Annette Szumski
    Lisa Marshall
    Paul Emery
    Arthritis Research & Therapy, 21
  • [43] Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab
    Sousa, Paula
    Patita, Marta
    Arroja, Bruno
    Lago, Paula
    Rosa, Isadora
    de Sousa, Helena Tavares
    Ministro, Paula
    Mocanu, Irina
    Vieira, Ana
    Castela, Joana
    Moleiro, Joana
    Roseira, Joana
    Cancela, Eugenia
    Portela, Francisco
    Correia, Luis
    Santiago, Mafalda
    Dias, Sandra
    Alves, Catarina
    Afonso, Joana
    Dias, Claudia Camila
    Magro, Fernando
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (05) : 737 - 743
  • [44] Clinical features of patients with Graves' disease undergoing remission lifter antithyroid drug treatment
    Vitti, P
    Rago, T
    Chiovato, L
    Pallini, S
    Santini, F
    Fiore, E
    Rocchi, R
    Martino, E
    Pinchera, A
    THYROID, 1997, 7 (03) : 369 - 375
  • [45] Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves' disease patients during methimazole treatment
    Gallo, Daniela
    Bruno, Antonino
    Gallazzi, Matteo
    Cattaneo, Simona Antonia Maria
    Veronesi, Giovanni
    Genoni, Angelo
    Tanda, Maria Laura
    Bartalena, Luigi
    Passi, Alberto
    Piantanida, Eliana
    Mortara, Lorenzo
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [46] Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves' Disease Patients
    Schempp, Vera
    Cebeci, Ayse Nurcan
    Reinauer, Christina
    Woelfle, Joachim
    Doerr, Helmuth-Guenther
    Roosen, Marie-Therese
    Gohlke, Jonas
    Gohlke, Bettina
    THYROID, 2024, 34 (06) : 735 - 743
  • [47] Oxidation products and antioxidant markers in plasma of patients with graves' disease and toxic multinodular goiter: Effect of methimazole treatment
    Bednarek, J
    Wysocki, H
    Sowinski, J
    FREE RADICAL RESEARCH, 2004, 38 (06) : 659 - 664
  • [48] Reporting success rate at 12 months after percutaneous treatment for peripheral arterial disease: The impact of outcome criteria
    Muradin, GSR
    Bosch, JL
    Verstijnen, ACM
    Hunink, MGM
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 185 (01) : 46 - 50
  • [49] Dose-optimized thiopurine maintenance therapy is associated with a higher rate of endoscopic remission compared with methotrexate in the treatment of Crohn's disease
    Con, D.
    Vasudevan, A.
    Parthasarathy, N.
    Bishara, M.
    Luber, R.
    Joshi, N.
    Wan, A.
    Rickard, J.
    Sparrow, M.
    Gibson, P.
    Vanlangenberg, D.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 128 - 128
  • [50] IODINE PERCHLORATE DISCHARGE TEST BEFORE AND AFTER ONE-YEAR OF METHIMAZOLE TREATMENT OF HYPERTHYROID GRAVES-DISEASE
    ROTI, E
    MINELLI, R
    GARDINI, E
    BIANCONI, L
    SALVI, M
    GAVARUZZI, G
    UGOLOTTI, G
    BRAVERMAN, LE
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (03): : 795 - 799
12345